Formal Meetings Between FDA and Biopharma Companies: New Draft Guidance
By Zachary Brennan -
Published 02 January 2018
Know the difference between a Type A, Type B and Type C meeting with the US Food and Drug Administration (FDA)? New draft guidance released last week will help biopharma companies understand how to conduct such meetings and what to expect.
Categories: News, US, FDA, Biologics and biotechnology, Drugs, Government affairs, Research and development
Tags: formal FDA meetings, PDUFA VI, user fee goal dates for meetings, Type A meeting